| Literature DB >> 28387999 |
Lin Sun1, Yinlong Kong1, Manqing Cao2,3, Hongyuan Zhou1, Huikai Li1, Yunlong Cui1, Feng Fang1, Wei Zhang1, Jiafeng Li1, Xiaolin Zhu1, Qiang Li1, Tianqiang Song1, Ti Zhang1.
Abstract
Metastasis is a serious risk that may occur during the treatment of hepatocellular carcinoma (HCC), preventing many patients from being surgical candidates and contributing to poor prognosis. Hypoxia has been proved an important factor of metastasis through the epithelial-mesenchymal transition (EMT) pathway. Acetyl-CoA synthase 2 (ACSS2) provides an acetyl group for the acetylation of hypoxia-inducible factor (HIF)-2α, and this epigenetic modification affects the activity of HIF-2α and the subsequent EMT process. Here, we showed that ACSS2 expression was negatively correlated with HCC malignancy. Knockdown of ACSS2 increased the invasion and migration ability of HCC cells and promoted EMT without increasing the total protein level of HIF-2α, even in hypoxic conditions. The immunoprecipitation assay revealed downregulated acetylation levels of HIF-2α after ACSS2 knockdown in hypoxic conditions, which resulted in enhanced HIF-2α activity. Finally, decreased expression of ACSS2 was found to be related to advanced stage and poor overall survival and disease-free survival rates in a cohort of patients with HCC. In conclusion, ACSS2 plays an important role in the acetylation process of HIF-2α, which effectively modifies the activity of HIF-2α under hypoxic conditions and greatly impacts on the prognosis of patients with HCC.Entities:
Keywords: ACSS2; Acetylation; HIF-2α; hepatocellular carcinoma; metastasis
Mesh:
Substances:
Year: 2017 PMID: 28387999 PMCID: PMC5497799 DOI: 10.1111/cas.13252
Source DB: PubMed Journal: Cancer Sci ISSN: 1347-9032 Impact factor: 6.716
Figure 1Acetyl‐CoA synthase 2 (ACSS2) expression in hepatocellular carcinoma (HCC) cell lines and patients. (a) Expression of ACSS2 in four HCC cell lines was detected by Western blot analysis. The data showed that a higher degree of malignancy was associated with lower ACSS2 protein expression in the HCC cell lines. The LO2 cell line, which was derived from normal liver tissue, was used as a control. The LM3 and MHCC97H cell lines are highly metastatic compared with the MHCC97L cell line, whereas the Hep3B cell line shows almost no metastatic ability. All cell lines were maintained in normoxic conditions. (b) ACSS2 expression was also detected in 12 pairs of human HCC carcinoma (c) and non‐carcinoma (N) tissues by Western blot analysis. Non‐carcinoma tissues showed higher expression. (c) Another 13 pairs of human HCC and non‐carcinoma tissues were assessed by RT‐PCR, and a similar result was obtained. Average (Avg.) expression of ACSS2 mRNA in the carcinoma and non‐carcinoma tissues is shown. Data are shown as the mean ± SD of three independent experiments. Error bars represent SD. *P < 0.05; **P < 0.01.
Background characteristics of patients with hepatocellular carcinoma
| Parameter | Yes | No |
|---|---|---|
| Age, ≥50 years | 19 | 6 |
| Gender, male | 23 | 2 |
| Tumor size, ≥5 cm | 12 | 13 |
| Tumor number, multiple | 7 | 18 |
| Satellite lesions | 11 | 14 |
| Portal vein invasion | 10 | 15 |
| Microvascular invasion | 17 | 8 |
| Cirrhosis | 20 | 5 |
| Clinical stage, advanced | 11 | 14 |
| Histological grade, poor | 8 | 17 |
| HBV infection | 21 | 4 |
| HCV infection | 0 | 25 |
HBV, hepatitis B virus; HCV, hepatitis C virus.
Figure 2Downregulation of acetyl‐CoA synthase 2 (ACSS2) increased the invasion and migration of hepatocellular carcinoma (HCC) cells in hypoxic conditions. (a) siRNA knockdown was verified by Western blot analysis in MHCC97H cells. Grayscale analysis of the three replicates is shown as a histogram. ACSS2 expression was normalized to β‐actin. (b,c) Transwell invasion experiment and scratch test showed that downregulation of ACSS2 resulted in increased invasiveness and migration of HCC cells in hypoxic conditions. Data are shown as mean ± SD of three independent experiments. Error bars represent SD. *P < 0.05; **P < 0.01. NC, normal control.
Figure 3Knockdown of acetyl‐CoA synthase 2 (ACSS2) promoted epithelial–mesenchymal transition of hepatocellular carcinoma cells without increasing hypoxia‐inducible factor‐2α (HIF‐2α). (a) Morphology of MHCC97H after siRNA interference in normoxic and hypoxic conditions. (b) Western blot images show that there were more N‐cadherin, vimentin, and Snail, and less E‐cadherin expression in the siACSS2 cells compared to the normal control (NC) cells in hypoxic conditions. Grayscale analysis of N‐cadherin and E‐cadherin is shown as histograms, which represent three replicates. Data in the histograms are normalized to β‐actin. (c) There was no difference in HIF‐2α expression between the siACSS2 group and the NC group. Grayscale analysis of HIF‐2α is also shown. Error bars represent SD. *P < 0.05; **P < 0.01.
Figure 4Knockdown of acetyl‐CoA synthase 2 (ACSS2) induced deacetylation of hypoxia‐inducible factor‐2α (HIF‐2α) and enhanced the activity of HIF‐2α in hypoxic conditions. (a,b) RT‐PCR and Western blot results revealed that ACSS2 knockdown enhanced the expression of some HIF‐2α downstream molecules in hypoxic conditions. Grayscale analysis of transforming growth factor α (TGFα) and ACSS2 is shown as histograms. Data are normalized to β‐actin and are shown as mean ± SD of three independent experiments. (c) Immunoprecipitation (IP) showed that ACSS2 knockdown led to higher deacetylated HIF‐2α expression under hypoxic conditions. Error bars represent SD. *P < 0.05; **P < 0.01. GLUT1, glucose transporter 1; PGK1, phosphoglycerate kinase 1; VEGF, vascular endothelial growth factor.
Clinical characteristics and laboratory parameters of patients with hepatocellular carcinoma according to ACSS2 expression level
| Parameter |
|
|
|
|
|---|---|---|---|---|
| Age, years | ||||
| <50 | 35 | 21 | 14 | 0.193 |
| ≥50 | 75 | 35 | 40 | |
| Gender | ||||
| Male | 98 | 48 | 50 | 0.247 |
| Female | 12 | 8 | 4 | |
| Tumor size, cm | ||||
| <5 | 52 | 25 | 27 | 0.574 |
| ≥5 | 58 | 31 | 27 | |
| Tumor number | ||||
| Single | 76 | 35 | 41 | 0.128 |
| Multiple | 34 | 21 | 13 | |
| Satellite lesions | ||||
| No | 59 | 21 | 38 | 0.001 |
| Yes | 51 | 35 | 16 | |
| Portal vein invasion | ||||
| No | 58 | 21 | 37 | 0.001 |
| Yes | 52 | 35 | 17 | |
| Microvascular invasion | ||||
| No | 35 | 10 | 25 | 0.001 |
| Yes | 75 | 46 | 29 | |
| Cirrhosis | ||||
| No | 22 | 5 | 17 | 0.003 |
| Yes | 88 | 51 | 37 | |
| Clinical stage | ||||
| Stage I and II | 63 | 22 | 41 | <0.001 |
| Stage III and IV | 47 | 34 | 13 | |
| Histological grade | ||||
| Well | 82 | 38 | 44 | 0.101 |
| Poor | 28 | 18 | 10 | |
| HIF‐2α expression | ||||
| Low expression | 60 | 27 | 33 | 0.174 |
| High expression | 50 | 29 | 21 | |
| TGFα expression | ||||
| Low expression | 65 | 28 | 37 | 0.048 |
| High expression | 45 | 28 | 17 | |
HIF‐2α, hypoxia‐inducible factor‐2α; TGFα, transforming growth factor α. *P ≤ 0.05.
Figure 5Low acetyl‐CoA synthase 2 (ACSS2) expression was associated with poor prognosis and progression in hepatocellular carcinoma (HCC) patients. (a) Representative images of ACSS2 expression in HCC tumors were obtained by immunohistochemical staining. (b) The relationship between ACSS2 immunohistochemical staining intensity and clinical stage is presented as histograms. Data indicate that more advanced HCC tumors (stage III and IV) show much less intense staining of ACSS2 protein than early stage tumors (stage I and II). The Y‐axis indicates the frequency of patients in different groups. (c) Decreased expression of ACSS2 was related to poor prognosis (P < 0.05). DFS, disease‐free survival; OS, overall survival. (d) Precancerous tissue (PR) also showed less ACSS2 expression than corresponding non‐carcinoma tissue (N). Furthermore, vascular invasion tissue (portal vein tumor thrombus, PVTT) showed lower ACSS2 expression than non‐carcinoma tissue (N), which was similar to its primary tumor (C).
Analysis of prognostic factors influencing overall survival (OS) and disease‐free survival (DFS) in patients with hepatocellular carcinoma
| OS | DFS | |||||
|---|---|---|---|---|---|---|
|
| χ2‐test |
|
| χ2‐test |
| |
| Age, years | ||||||
| <50 | 35 | 3.494 | 0.062 | 35 | 1.502 | 0.220 |
| ≥50 | 75 | 75 | ||||
| Gender | ||||||
| Male | 98 | 0.660 | 0.416 | 98 | 0.637 | 0.425 |
| Female | 12 | 12 | ||||
| Tumor size, cm | ||||||
| <5 | 52 | 4.621 | 0.032 | 52 | 1.304 | 0.253 |
| ≥ 5 | 58 | 58 | ||||
| Tumor number | ||||||
| Single | 76 | 11.437 | 0.001 | 76 | 11.948 | 0.001 |
| Multiple | 34 | 34 | ||||
| Satellite lesions | ||||||
| No | 59 | 20.775 | <0.001 | 59 | 17.669 | <0.001 |
| Yes | 51 | 51 | ||||
| Portal vein invasion | ||||||
| No | 58 | 12.616 | <0.001 | 58 | 14.445 | <0.001 |
| Yes | 52 | 52 | ||||
| Microvascular invasion | ||||||
| No | 35 | 13.368 | <0.001 | 35 | 10.825 | 0.010 |
| Yes | 75 | 75 | ||||
| Cirrhosis | ||||||
| No | 22 | 2.578 | 0.108 | 22 | 6.321 | 0.012 |
| Yes | 88 | 88 | ||||
| Clinal stage | ||||||
| Stage I and II | 63 | 41.424 | <0.001 | 63 | 26.147 | <0.001 |
| Stage III and IV | 47 | 47 | ||||
| Histological grade | ||||||
| Well | 82 | 0.535 | 0.465 | 82 | 0.062 | 0.804 |
| Poor | 28 | 28 | ||||
| HIF‐2α expression | ||||||
| Low expression | 60 | 7.063 | 0.008 | 60 | 1.998 | 0.158 |
| High expression | 50 | 50 | ||||
| TGFα expression | ||||||
| Low expression | 65 | 4.294 | 0.038 | 65 | 0.841 | 0.359 |
| High expression | 45 | 45 | ||||
|
| ||||||
| Low expression | 56 | 9.980 | 0.002 | 56 | 7.048 | 0.008 |
| High expression | 54 | 54 | ||||
HIF‐2α, hypoxia‐inducible factor‐2α; TGFα, transforming growth factor α. *P ≤ 0.05.